PURPOSE: Antioxidant supplements may reduce age-related macular degeneration (AMD) progression. The macular carotenoids are of particular interest because of their biochemical, optical, and anatomic properties. This classic twin study was designed to determine the heritability of macular pigment (MP) augmentation in response to supplemental lutein (L) and zeaxanthin (Z). METHODS: A total of 322 healthy female twin volunteers, aged 16-50 years (mean 40 ± 8.7) was enrolled in a prospective, nonrandomized supplement study. Macular pigment optical density (MPOD) measurements using two techniques (2-wavelength fundus autofluorescence [AF] and heterochromatic flicker photometry [HFP]), and serum concentrations of L and Z, were recorded at baseline, and at 3 and 6 months following daily supplementation with 18 mg L and 2.4 mg Z for a study period of 6 months. RESULTS: At baseline, mean MPOD was 0.44 density units (SD 0.21, range 0.04-1.25) using HFP, and 0.41 density units (SD 0.15) using AF. Serum L and Z levels were raised significantly from baseline following 3 months' supplementation (mean increase 223% and 633%, respectively, P < 0.0001 for both), with no MPOD increase. After 6 months' supplementation, a small increase in MPOD was seen (mean increase 0.025 ± 0.16, P = 0.02, using HFP). Subdivision of baseline MPOD into quartiles revealed that baseline levels made no difference to the treatment effect. Genetic factors explained 27% (95% confidence interval [CI] 7-45) of the variation in MPOD response. Distribution profiles of macular pigment did not change in response to supplementation. CONCLUSIONS: MPOD response to supplemental L and Z for a period of 6 months was small (an increase over baseline of 5.7% and 3.7%, measured using HFP and AF, respectively), and was moderately heritable. Further study is indicated to investigate the functional and clinical impact of supplementation with the macular carotenoids.
PURPOSE: Antioxidant supplements may reduce age-related macular degeneration (AMD) progression. The macular carotenoids are of particular interest because of their biochemical, optical, and anatomic properties. This classic twin study was designed to determine the heritability of macular pigment (MP) augmentation in response to supplemental lutein (L) and zeaxanthin (Z). METHODS: A total of 322 healthy female twin volunteers, aged 16-50 years (mean 40 ± 8.7) was enrolled in a prospective, nonrandomized supplement study. Macular pigment optical density (MPOD) measurements using two techniques (2-wavelength fundus autofluorescence [AF] and heterochromatic flicker photometry [HFP]), and serum concentrations of L and Z, were recorded at baseline, and at 3 and 6 months following daily supplementation with 18 mg L and 2.4 mg Z for a study period of 6 months. RESULTS: At baseline, mean MPOD was 0.44 density units (SD 0.21, range 0.04-1.25) using HFP, and 0.41 density units (SD 0.15) using AF. Serum L and Z levels were raised significantly from baseline following 3 months' supplementation (mean increase 223% and 633%, respectively, P < 0.0001 for both), with no MPOD increase. After 6 months' supplementation, a small increase in MPOD was seen (mean increase 0.025 ± 0.16, P = 0.02, using HFP). Subdivision of baseline MPOD into quartiles revealed that baseline levels made no difference to the treatment effect. Genetic factors explained 27% (95% confidence interval [CI] 7-45) of the variation in MPOD response. Distribution profiles of macular pigment did not change in response to supplementation. CONCLUSIONS: MPOD response to supplemental L and Z for a period of 6 months was small (an increase over baseline of 5.7% and 3.7%, measured using HFP and AF, respectively), and was moderately heritable. Further study is indicated to investigate the functional and clinical impact of supplementation with the macular carotenoids.
Authors: Tos T J M Berendschot; Wendy M R Broekmans; Ineke A A Klöpping-Ketelaars; Alwine F M Kardinaal; Geert Van Poppel; Dirk Van Norren Journal: Arch Ophthalmol Date: 2002-12
Authors: E J Johnson; B R Hammond; K J Yeum; J Qin; X D Wang; C Castaneda; D M Snodderly; R M Russell Journal: Am J Clin Nutr Date: 2000-06 Impact factor: 7.045
Authors: Eithne E Connolly; Stephen Beatty; James Loughman; Alan N Howard; Michael S Louw; John M Nolan Journal: Invest Ophthalmol Vis Sci Date: 2011-11-29 Impact factor: 4.799
Authors: Shiao Hui Melissa Liew; Clare E Gilbert; Tim D Spector; John Mellerio; John Marshall; Fredericus J van Kuijk; Stephen Beatty; Fred Fitzke; Christopher J Hammond Journal: Invest Ophthalmol Vis Sci Date: 2005-12 Impact factor: 4.799
Authors: John Nolan; Orla O'Donovan; Heather Kavanagh; Jim Stack; Michael Harrison; Annalouise Muldoon; John Mellerio; Stephen Beatty Journal: Invest Ophthalmol Vis Sci Date: 2004-11 Impact factor: 4.799
Authors: Kristin J Meyers; Elizabeth J Johnson; Paul S Bernstein; Sudha K Iyengar; Corinne D Engelman; Chitra K Karki; Zhe Liu; Robert P Igo; Barbara Truitt; Michael L Klein; D Max Snodderly; Barbara A Blodi; Karen M Gehrs; Gloria E Sarto; Robert B Wallace; Jennifer Robinson; Erin S LeBlanc; Gregory Hageman; Lesley Tinker; Julie A Mares Journal: Invest Ophthalmol Vis Sci Date: 2013-03-28 Impact factor: 4.799
Authors: Kristin J Meyers; Julie A Mares; Robert P Igo; Barbara Truitt; Zhe Liu; Amy E Millen; Michael Klein; Elizabeth J Johnson; Corinne D Engelman; Chitra K Karki; Barbara Blodi; Karen Gehrs; Lesley Tinker; Robert Wallace; Jennifer Robinson; Erin S LeBlanc; Gloria Sarto; Paul S Bernstein; John Paul SanGiovanni; Sudha K Iyengar Journal: Invest Ophthalmol Vis Sci Date: 2014-01-29 Impact factor: 4.799